AMDHD1 Antibody
- Known as:
- AMDHD1 Antibody
- Catalog number:
- 39599
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Signalway
- Gene target:
- AMDHD1 Antibody
Related genes to: AMDHD1 Antibody
- Gene:
- AMDHD1 NIH gene
- Name:
- amidohydrolase domain containing 1
- Previous symbol:
- -
- Synonyms:
- MGC35366
- Chromosome:
- 12q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 2006-01-17
- Date modifiied:
- 2016-07-14
Related products to: AMDHD1 Antibody
Related articles to: AMDHD1 Antibody
- - Source: PubMed
Publication date: 2026/04/06
Li YuhuiChen RongxiMo HuiWu QiLi ZhunHe SaiqiZhou AijunYu ShuhuiDuan ChaohuiNi WenLi Jianming - Cerebral white matter hyperintensities (WMHs) on MRI are part of the spectrum of age-related brain vascular injury and are associated with increased risk of stroke and dementia. Genome-wide association studies (GWASs) conducted mostly in populations of European ancestry have identified several genetic loci. Although Hispanic/Latino adults have a greater burden of WMHs than their non-Hispanic White counterparts, they are vastly underrepresented in genetic studies. We sought to characterize the genetic architecture of WMHs in a Hispanic/Latino cohort by investigating the transferability of known WMH genetic loci and by leveraging Hispanic/Latino genetic diversity to map novel loci. - Source: PubMed
Publication date: 2025/10/02
Fornage MyriamXia RuiOrdonez AdrianaSofer TamarIsasi Carmen RLipton Richard BStickel Ariana MTarraf WassimGonzalez Hector MDecarli Charles S - Cholangiocarcinoma (CCA) is a malignant tumor of the digestive system, characterized by its aggressive behavior and the absence of effective therapeutic biomarkers. Although recent studies have implicated AMDHD1 in tumor formation, its role in CCA development has been insufficiently explored. We utilized multiple bioinformatic datasets alongside 108 clinical samples to examine AMDHD1 expression in CCA. Then, in vitro and in vivo experiments were conducted to assess its impact on tumor growth and metastasis. Furthermore, proteomic analysis and immunoprecipitation mass spectrometry were employed to identify the downstream effectors of AMDHD1. We discovered that AMDHD1 was down-regulated in CCA and this down-regulation was associated with adverse clinicopathological features and prognosis. We also demonstrated that overexpression of AMDHD1 hindered G1/S progression in the cell cycle and promoted apoptosis, thereby inhibiting tumor growth and metastasis. Mechanistically, we found that AMDHD1 operated in a TGF-β-dependent manner and the inhibition of TGF-β signaling abrogated the effect of AMDHD1 overexpression on CCA cells. Specifically, AMDHD1 inhibited the ubiquitination and degradation of the SMAD4 protein through binding to the MH2 domain and synergistically enhanced SMAD2/3 phosphorylation, which activated of TGF-β signaling pathway and resulted in the suppression of CCA cell proliferation and migration. Our study identifies AMDHD1 as a significant prognostic biomarker and a tumor suppressor in CCA. It underscores the pivotal role of the AMDHD1/TGF-β signaling pathway in the development and progression of CCA. - Source: PubMed
Publication date: 2024/08/14
Ma ZuyiSun JiaLi ZhenchongHuang ShanzhouLi Binglu - Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease. Metabolism-related genes significantly influence the onset and progression of the disease. Hence, it is necessary to screen metabolism-related biomarkers for the diagnosis and treatment of NAFLD patients. - Source: PubMed
Publication date: 2023/09/11
Jiang HuaHu YangZhang ZhiboChen XujiaGao Jianpeng - The associations of vitamin D level with venous thromboembolism (VTE) reported in observational studies, whereas these causal associations were uncertain in European population. Therefore, we used Mendelian randomization (MR) method to explore the causal associations between 25-hydroxyvitamin D (25(OH)D) concentrations and the risk of VTE and its subtypes [including deep vein thrombosis (DVT) and pulmonary embolism (PE)]. - Source: PubMed
Publication date: 2023/05/19
Zhang XiaoyuSun WenLi NingJian XueningGeng TaoWu LijuanWang YouxinWang BaoguoZheng Deqiang